Structural characterization of a galactoglucomannan with anti-neuroinflammatory activity from Ganoderma lucidum

Mar 29, 2024Carbohydrate polymers

Structure of a sugar compound from Ganoderma lucidum that may reduce brain inflammation

AI simplified

Longevity & Aging on OpenScience ↗PubMed ↗DOI ↗

Abstract

The crude polysaccharide GL70 significantly improved spatial learning and memory function in a rat model of Alzheimer's disease.

GL70 reduced anxiety symptoms in a lipopolysaccharide-induced rat model of Alzheimer's disease.
A galactoglucomannan, GLP70-1-2, was isolated and structurally characterized from GL70.
GLP70-1-2 showed efficacy in lowering pro-inflammatory factors in LPS-activated BV2 cells.
The anti-neuroinflammatory activity of GLP70-1-2 may be linked to the TLR4/MyD88/NF-κB signaling pathway.
Further investigation is needed to fully understand the structure-activity relationship of G. lucidum polysaccharides.

AI simplified

According to traditional Chinese medicine theory, Ganoderma lucidum (G. lucidum) presents certain effects for nourishing nerves and calming the mind. G. lucidum polysaccharides (GLPs) have various biological activities; however, the structural characterization and the structure-activity relationship in anti-neuroinflammation of GLPs needs to be further investigated. In this work, the crude polysaccharide GL70 exhibited a remarkable impact on enhancing the spatial learning and memory function, as well as reducing the anxiety symptoms of the lipopolysaccharide (LPS)-induced rat model of Alzheimer's disease (AD). A galactoglucomannan (GLP70-1-2) was isolated from GL70, and characterized by monosaccharide composition, partial acid hydrolysis, methylation, and NMR analysis. The backbone of GLP70-1-2 was →6)-α-D-glcp-(1 → 6)-β-D-galp-(1 → [6)-β-D-manp-(1] → 4)-α-D-Glcp-(1 → 6)-α-D-glcp-(1 → 2)-β-D-galp-(1 → [4)-α-D-glcp-(1 → 6)-β-D-manp-(1 → 2)-β-D-galp-(1] → 6)-β-D-glcp-(1 → 6)-β-D-glcp-(1→ with two side chains attached to O-4 of →6)-β-D-galp-(1→ and O-3 of →6)-β-D-glcp-(1→, respectively. In addition, GLP70-1-2 exhibited remarkable efficacy in decreasing the level of pro-inflammatory factors in LPS-activated BV2 cells through the TLR4/MyD88/NF-κB pathway. Collectively, GLP70-1-2 exhibited significant anti-neuroinflammatory activity and may have the potential for developing as a drug for AD. 3 2

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Structural characterization of a galactoglucomannan with anti-neuroinflammatory activity from Ganoderma lucidum

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the longevity & aging brief